Novo Nordisk says Wegovy launch in India will be without supply constraints
COPENHAGEN - Danish drugmaker Novo Nordisk will launch its weight-loss drug Wegovy in India without any supply constraints, a company spokesperson said on Tuesday.
"We are committed to addressing the unmet needs of patients living with chronic diseases such as obesity, thus this will be a full launch," the spokesperson said in an emailed statement.
"We do not anticipate any supply constraints and are confident of stable supply of the product in India."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Arabian Business
12 hours ago
- Arabian Business
Middle East pharma market to hit $36bn by 2028 as GCC accelerates innovation and manufacturing
The Middle East's life sciences sector is poised for rapid growth, with the pharmaceutical market expected to reach $36bn by 2028, according to the latest EMEA Life Sciences Industry Perspective and Cluster Report by JLL. Supported by major government investment in research, manufacturing infrastructure, and digital transformation, the region's market is on track to grow at a compound annual growth rate (CAGR) of 7.7 per cent from 2023. The report highlights the strategic pivot across the Gulf Cooperation Council (GCC) to develop local capabilities, reduce import dependence, and diversify national economies. Middle East pharma market boom For the first time, the JLL report includes a detailed focus on the Middle East, revealing how the region is transforming into a hub for life sciences innovation, spanning biopharma research, digital health, and pharmaceutical manufacturing. These trends are reshaping demand for specialised real estate, including flexible R&D spaces, digital health facilities, and state-of-the-art manufacturing hubs. Mireille Azzam, Head of Strategic Consulting, JLL Middle East and Africa (MEA) said: 'Innovation is critical for success in the life sciences industry, and the GCC is building self-reliance by incubating innovative ventures and creating a collaborative environment to scale research and expand its pool of skilled workforce. 'From flexible lab designs and resilient building systems, the increased focus on creating spaces primed for scientific breakthroughs and growth is directly translating into a dynamic real estate market. 'The growing demand for purpose-built facilities will support groundbreaking research, advanced manufacturing, and drive digital transformation, laying a strong foundation for the future growth of the region's evolving life sciences ecosystem.' Key factors accelerating the industry include: Government incentives for local drug manufacturing and biosimilar development Rising prevalence of chronic diseases and demand for personalised medicine Strong focus on telehealth, AI diagnostics, and remote patient monitoring Increased venture capital funding and AI-powered innovation across labs and distribution Strategic locations with advanced logistics and energy-efficient infrastructure The report outlines how major GCC countries are becoming hotspots for life sciences clusters: Biopharma R&D Dubai Science Park and Qatar Science and Technology Park are regional innovation centres Saudi Arabia is expanding its role in drug discovery through strategic partnerships Digital Health Dubai Healthcare City, Healthpoint Abu Dhabi, and NEOM are leading the push in AI, telehealth, and health-tech startups Pharmaceutical Manufacturing Jebel Ali Free Zone, Dubai Industrial City, King Abdullah Economic City, and Sudair Industrial City offer state-of-the-art industrial parks Competitive advantages include low-cost energy, strategic geography, and high local content requirements The shift from public or owner-occupied labs to investor-supplied real estate is solving long-standing shortages of lab space. JLL notes that demand is now focused on next-generation lab facilities, resilient building systems and more sustainable lab designs This change is helping the GCC region align with global leaders like the Golden Triangle (UK), Johannesburg, and Singapore in life sciences innovation. The region's academic strength also plays a key role, with institutions like King Saud University, Qatar University, and United Arab Emirates University earning recognition in global life sciences rankings.
Zawya
17 hours ago
- Zawya
Middle East pharma market on track for $36bln by 2028
JLL's EMEA Life Sciences Industry Perspective and Cluster Report reveals AI and venture capital are fuelling a surge in demand for next-generation labs The Middle East's pharmaceutical market is projected to reach US$36 billion by 2028, with a CAGR of 7.7% from 2023 GCC governments are prioritizing digital transformation and investing in local generic drug manufacturing and biosimilar development to boost sector growth Dubai, United Arab Emirates: Fuelled by significant government investments in R&D and manufacturing infrastructure, and a strategic push towards greater local innovation and production, the Middle East's life sciences industry is poised for substantial growth, according to JLL's latest EMEA Life Sciences Industry Perspective and Cluster Report. The region's pharmaceutical market is projected to reach US$36 billion by 2028, and this robust expansion, set for a Compound Annual Growth Rate (CAGR) of 7.7% from 2023, is further amplified by digital transformation initiatives and comprehensive industrialisation strategies across the Gulf Cooperation Council (GCC). As the life sciences market develops globally, countries in the GCC are accelerating their capabilities in the sector to boost innovation, reduce import reliance, and diversify their economies. The JLL report, which explores the key drivers shaping EMEA's life sciences industry and its impact on real estate markets, has included a high-level overview of the Middle East for the first time. The report reveals that the GCC's pivot towards becoming a global hub for life sciences innovation, research, and production is boosting demand for specialised real estate, including adequate office spaces for R&D and digital health, and manufacturing locations that require warehouse and distribution assets. Mireille Azzam, Head of Strategic Consulting, JLL Middle East and Africa (MEA) said:'Innovation is critical for success in the life sciences industry, and the GCC is building self-reliance by incubating innovative ventures and creating a collaborative environment to scale research and expand its pool of skilled workforce. From flexible lab designs and resilient building systems, the increased focus on creating spaces primed for scientific breakthroughs and growth is directly translating into a dynamic real estate market. The growing demand for purpose-built facilities will support groundbreaking research, advanced manufacturing, and drive digital transformation, laying a strong foundation for the future growth of the region's evolving life sciences ecosystem.' Amidst increasing global competition and tariff uncertainty, JLL's latest report highlights several overarching trends shaping the life sciences real estate landscape across EMEA. Artificial Intelligence (AI) and venture capital are driving demand for next-generation labs, and the report highlights AI's dual impact in accelerating scientific discovery and revolutionising real estate management through increased efficiency from research to distribution. New supply delivered by investors is progressively addressing historical lab space shortages, shifting away from public or owner-occupier driven models, with top-tier assets in prime locations expected to prevail. The JLL report highlights that the sector's commitment to sustainability is driving demand for greener lab buildings. These dynamics underscore how life sciences clusters, from Europe to the Middle East and Africa, possess distinctive strengths, with locations like the Golden Triangle, Johannesburg, and Riyadh leading in biopharma research, while others excel in digital health or manufacturing. The GCC's increasing commitment to life sciences JLL's analysis of the major life sciences city-clusters in the GCC reveals significant transformations across the three prominent subsectors of Biopharma R&D, Digital Health and Tech R&D, and Pharmaceutical Manufacturing. Driven by the increasing prevalence of chronic diseases and a focus on personalised medicine and genomics research, JLL notes a profound shift in the Biopharma and drug discovery sector. As targeted therapies gain prominence, government investments in local generic drug manufacturing and biosimilar development are accelerating, with innovative research in cell and gene therapy also primed for significant growth. Dubai Science Park in the UAE and Qatar Science and Technology Park have emerged as regional hubs for biopharma R&D, while Saudi Arabia's position in the regional drug discovery landscape is strengthened through strategic partnerships and ongoing investments in pharmaceutical research and manufacturing. To improve accessibility, efficiency, and patient outcomes in the healthcare sector, GCC governments have prioritised digital transformation, driving growth in telehealth, remote patient monitoring, and AI-powered diagnostics. The emergence of health-tech startups and a growing emphasis on preventive healthcare are also contributing to sector growth. Regional hubs such as the UAE's Dubai Healthcare City and Healthpoint in Abu Dhabi, and Saudi Arabia's NEOM project are driving the surge in digital health adoption and investment, and fostering innovation and attracting talent. Through investments in industrial parks and by providing incentives for manufacturers, GCC governments are diversifying the region's Pharmaceutical Manufacturing sector. Alongside the adoption of advanced manufacturing technologies to boost efficiencies, growth in this sector is driven by affordable energy, strategic geographic locations, and increasing local content requirements. The UAE's Jebel Ali Free Zone and Dubai Industrial City, alongside Saudi Arabia's King Abdullah Economic City and Sudair Industrial City, stand out as key manufacturing hubs. These locations offer advanced infrastructure and logistical advantages, successfully attracting both domestic and international pharmaceutical companies. The region's commitment to life sciences is further bolstered by its strong academic credentials, as institutions such as King Saud University in KSA, Qatar University, and the United Arab Emirates University earn top spots in global life sciences university rankings. About JLL For over 200 years, JLL (NYSE: JLL), a leading global commercial real estate and investment management company, has helped clients buy, build, occupy, manage and invest in a variety of commercial, industrial, hotel, residential and retail properties. A Fortune 500® company with annual revenue of $23.4 billion and operations in over 80 countries around the world, our more than 112,000 employees bring the power of a global platform combined with local expertise. SEE A BRIGHTER WAYSM. About JLL MEA Across the Middle East and Africa (MEA) JLL is a leading player in the real estate and hospitality services markets. The firm has worked in 35 countries across the region and employs over 2000 internationally qualified professionals across its offices in Dubai, Abu Dhabi, Riyadh, Jeddah, Al Khobar, Cairo, Casablanca, Cape Town, Johannesburg and Nairobi.
Zawya
18 hours ago
- Zawya
South Africa: Medshield is committed to building a sustainable healthcare future
Are you curious about what makes businesses stand out in our current environment? It's certainly not about the bottom line and the financials anymore. It's about how they impact the world – the environment, the societies in which they operate, and their governance structures. Environmental, Social, and Governance (ESG) principles have become indispensable in a world grappling with climate change, social inequalities, and corporate accountability. While sectors like mining, energy, and manufacturing have typically been under the ESG spotlight, healthcare is now stepping into focus. Integrating ESG principles is crucial for medical schemes to ensure the future sustainability of healthcare. Factors such as escalating costs, the rise of lifestyle-related diseases, and the environmental impact of medical waste make ESG adoption necessary. Medshield Medical Scheme aligns sustainability with healthcare excellence by developing an ESG roadmap featuring clear corporate sustainability goals. This effort sets the benchmark for responsible healthcare funding in South Africa, paving the way for a more resilient healthcare system. Learning from South African ESG leaders Medshield acknowledges the importance of gaining insights from industry leaders who have effectively integrated ESG principles into their business models. Locally, Life Healthcare is actively driving sustainable healthcare by incorporating energy efficiency and water-saving measures across its hospital network. Aspen Pharmacare, one of South Africa's largest pharmaceutical companies, has embedded ESG principles into its global operations – most notably with sustainable manufacturing practices and community health support initiatives. Sanlam has demonstrated leadership in sustainable investment practices, governance transparency, and transformation targets in the insurance sector, aligning financial strength with social progress. Novartis South Africa also contributes to local ESG progress through public-private partnerships to expand access to healthcare and drive inclusive health equity. By benchmarking against these homegrown leaders and learning from their practical examples, Medshield aims to refine and strengthen its ESG roadmap. Although still in its preliminary stages, Medshield is laying the foundation for meaningful impact. 1. Environmental impact: Pollution and waste management Environmental sustainability is a fundamental ESG pillar, and healthcare providers must tackle pollution and waste management. The healthcare sector produces substantial medical, pharmaceutical, and electronic waste, which can result in severe environmental consequences if not meticulously managed. Life Healthcare has taken a proactive role in managing medical waste and improving energy usage within hospital environments. Aspen Pharmacare has also been recognised for its commitment to reducing environmental impact through improved production technologies and waste reduction systems. Inspired by these local initiatives, Medshield is exploring energy-efficient infrastructure and renewable energy solutions to reduce its environmental footprint and contribute to sustainable healthcare. 2. Social impact: Climate change and human health Climate change poses an escalating threat to public health. Rising temperatures and pollution levels contribute to lifestyle ailments such as hypertension, diabetes, and respiratory conditions. Medshield recognises its responsibility to mitigate these health risks through preventive healthcare programmes, chronic disease management, and promoting wellness benefits to its members. In parallel, Novartis South Africa continues to lead in raising awareness and improving access to treatment for chronic diseases, with a focus on underserved communities. Medshield similarly integrates ESG principles across its internal operations to ensure alignment with corporate sustainability goals and regulatory compliance while supporting climate resilience through health. 3. Corporate responsibility: Social initiatives and member engagement ESG leaders in South Africa prioritise healthcare access and equity. Medshield is committed to extending its corporate responsibility beyond its members. The Scheme supports community health initiatives, wellness programmes, and financial literacy education. Additionally, Medshield embeds ESG principles into its corporate culture – ensuring staff engagement and promoting awareness about lifestyle changes that contribute to improved health outcomes. Aspen Pharmacare, for instance, has significantly contributed to healthcare equity through community-based partnerships and access to essential medicines. Sanlam has also implemented financial literacy initiatives nationwide to drive socioeconomic upliftment. Medshield is actively learning from and contributing to this ecosystem of shared value creation. 4. Governance: The pillar of corporate sustainability Strong governance ensures transparency, accountability, and long-term sustainability. Medshield prides itself on having a robust governance structure and is adopting best practices to strengthen its corporate governance. The Scheme is exploring partnerships with ESG-focused healthcare networks for ongoing improvement and intends to integrate ESG reporting into its annual trustee and Annual General Meeting (AGM) reports to strengthen transparency and accountability. Sanlam's comprehensive sustainability disclosures and Life Healthcare's transparent ESG frameworks offer useful templates for Medshield's ongoing governance enhancement. By drawing from these examples, Medshield aims to ensure that ESG isn't a side initiative but a core part of the Scheme's operation. Medshield is a responsible corporate citizen Medshield's ESG journey signifies its dedication to being a responsible corporate citizen. By embedding ESG principles into its business model, Medshield enhances its reputation and safeguards its operations against emerging global challenges. As one of the pioneers among South African medical schemes in undertaking a structured ESG journey, Medshield is setting a noteworthy precedent. Its approach emphasises long-term resilience, sustainability, and member-centric healthcare solutions. As Medshield refines its ESG initiatives, the greater healthcare sector benefits from a model prioritising people, the planet, and strong governance. ESG is not merely a trend – it is the future of responsible healthcare, and Medshield is at the forefront of this transformation in South Africa. We invite all members, brokers, and stakeholders to join us in shaping a more sustainable and inclusive healthcare future.
